EDITION:

Search
Search
Close this search box.

Andrew Grieve, CEO of Zenabis talks about their contract cultivation partnership with Tantalus and their recent stock offering

Andrew Grieve is the CEO of Zenabis and he joined Business of Cannabis to talk about their agreement to grow Tantalus Labs genetics on contract as well as their stock offering to current shareholders – which has been the topic of conversation among those that follow publicly traded cannabis companies.

Related Posts

Related Posts

CONNECT

Related Posts

Related Posts

Recent Posts

Related Posts

Subscribe to our mailing list to receives daily updates!

We won’t spam you

Categories

Browse by Tags

CATEGORIES

EDITION

BUSINESS OF CANNABIS

© 2023 Prohibition Holdings Ltd. All Rights Reserved.

EDITION

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?